Baxter International Reports Q2 2026 Financial Results with Increased Net Income and Sales Growth

Baxter International Inc. reported its financial results for the second quarter and first half of 2026, revealing a net income of $126 million, or $0.24 per diluted share, for the three months ended June 30, 2026, compared to $91 million, or $0.18 per diluted share, for the same period in 2025. For the first six months of 2026, net income attributable to Baxter stockholders was $111 million, or $0.21 per diluted share, down from $217 million, or $0.42 per diluted share, in the prior year. The company’s net sales for the second quarter increased by 5% to $2.96 billion, up from $2.81 billion in the same quarter last year, while total net sales for the first half rose to $5.66 billion from $5.44 billion.

The company experienced a notable increase in gross margin, which reached $1.03 billion for the second quarter, compared to $991 million in the same period of 2025. However, the gross margin ratio slightly declined to 34.9% from 35.3% year-over-year. The increase in sales was attributed to strong performance in the Medical Products & Therapies segment, which saw net sales rise to $2.08 billion, up from $1.95 billion, driven by higher demand for infusion therapies and advanced surgery products. The Healthcare Systems & Technologies segment also reported growth, with sales increasing to $801 million from $767 million.

Baxter's operational changes included a strategic restructuring of its reportable segments, consolidating its previous three segments into two: Medical Products & Therapies and Healthcare Systems & Technologies. This restructuring aims to enhance decision-making and operational efficiency. The company also reported ongoing challenges related to supply chain disruptions and inflationary pressures, which have impacted manufacturing costs and pricing strategies. Additionally, Baxter noted that it has incurred business optimization charges related to restructuring efforts following the sale of its Kidney Care business, which was completed in January 2025.

Looking ahead, Baxter anticipates continued challenges from global economic conditions, including inflation and geopolitical events, which may affect customer demand and operational costs. The company is focused on improving efficiencies through automation and digital initiatives while managing the impacts of tariffs and supply chain constraints. Baxter's cash and cash equivalents stood at $2.15 billion as of June 30, 2026, providing a solid liquidity position to support its ongoing operations and strategic initiatives.